Patent ID: 9089586
Filing Date: 2015-07-28
Classification: A61K,A61P,C07H,C12P,Y02A

Abstract:
1. A levocarrimycin, wherein said levocarrimycin comprises a mixture of isovalerylspiramycin III, II and I as main components and contains isobutyrylspiramycin III and II, butyrylspiramycin III and II, propionylspiramycin III and II, as well as acetylspiramycin III and II, wherein the content of the isovalerylspiramycin III is not less than 30 wt %, the total content of isovalerylspiramycin III, II and I is not less than 60 wt %, and the content of acylspiramycin is 80-98 wt %; the specific optical rotation of said levocarrimycin is [α]=−52°˜57° in a solution of 0.02 g/ml chloroform at temperature of 25° C. wherein levoisovaleryispiramycin III is a crystal compound of levoisovalerylspiramycin III, levoisovaleryispiramycin II is a crystal compound of levoisovalerylspiramycin II, or levoisovaleryispiramycin I is a crystal compound of levoisovaleryispiramycin I; wherein, the crystal compound of levoisovaleryispiramycin III measured by an X-ray powder diffraction with Cu-Ka ray has characteristic peaks of 2θ at 8.0°, 10.0°, 11.2°, 11.7°, 16.4°, 19.1°, 19.6°, 20.0°, 21.4°, 22.9°, 23.6° and 29.4°; the crystal compound of levoisovalerylspiramycin II measured by the X-ray powder diffraction with Cu-Ka ray has characteristic peaks of 2θ at 10.0°, 11.6°, 16.4°, 17.3°, 19.1°, 21.2°, 22.1°, 22.7°, 26.4°, 26.9°, 27.5° and 31.5°; the crystal compound of levoisovaleryispiramycin I measured by the X-ray powder diffraction with Cu-Ka ray has characteristic peaks of 20 at 7.6°, 8.0°, 10.0°, 11.4°, 16.4°, 17.0°, 17.5°, 17.9°, 19.5°, 22.7°, 23.7° and 24.4°.